BRTX vs. TOI, ENZ, CCM, MRAI, OPGN, KDLY, OTRK, BGLC, MGRX, and ATPC
Should you be buying BioRestorative Therapies stock or one of its competitors? The main competitors of BioRestorative Therapies include Oncology Institute (TOI), Enzo Biochem (ENZ), Concord Medical Services (CCM), Marpai (MRAI), OpGen (OPGN), Kindly MD (KDLY), Ontrak (OTRK), BioNexus Gene Lab (BGLC), Mangoceuticals (MGRX), and Agape ATP (ATPC). These companies are all part of the "healthcare" industry.
BioRestorative Therapies vs.
Oncology Institute (NASDAQ:TOI) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends.
BioRestorative Therapies has lower revenue, but higher earnings than Oncology Institute. BioRestorative Therapies is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Oncology Institute has a net margin of -17.63% compared to BioRestorative Therapies' net margin of -2,697.08%. BioRestorative Therapies' return on equity of -98.49% beat Oncology Institute's return on equity.
Oncology Institute presently has a consensus price target of $2.50, suggesting a potential upside of 147.52%. BioRestorative Therapies has a consensus price target of $18.00, suggesting a potential upside of 650.00%. Given BioRestorative Therapies' higher probable upside, analysts clearly believe BioRestorative Therapies is more favorable than Oncology Institute.
36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are held by institutional investors. 9.5% of Oncology Institute shares are held by company insiders. Comparatively, 25.5% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Oncology Institute has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 63.13, suggesting that its stock price is 6,213% more volatile than the S&P 500.
Oncology Institute received 2 more outperform votes than BioRestorative Therapies when rated by MarketBeat users. However, 100.00% of users gave BioRestorative Therapies an outperform vote while only 66.67% of users gave Oncology Institute an outperform vote.
In the previous week, Oncology Institute had 1 more articles in the media than BioRestorative Therapies. MarketBeat recorded 3 mentions for Oncology Institute and 2 mentions for BioRestorative Therapies. Oncology Institute's average media sentiment score of 0.95 beat BioRestorative Therapies' score of 0.43 indicating that Oncology Institute is being referred to more favorably in the media.
Summary
Oncology Institute and BioRestorative Therapies tied by winning 8 of the 16 factors compared between the two stocks.
Get BioRestorative Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioRestorative Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:BRTX) was last updated on 1/31/2025 by MarketBeat.com Staff
